"A 100 beded Gastro superspecility Hospital located in the centre of the Surat city. Its a centre for GI Medicine, GI Surgery, GI Endoscopy, GI Cancer treament. Facility equipped with 24 x 7 ICU back up , Dialysis Unit, OT, Endosuites, OPD, Lounges,Auditorium etc."

During the past decade, Surat Institute of Digestive Sciences conducted 20 clinical trials. In the 10-year time frame, 20 clinical trials started and 3 clinical trials were completed, i.e. on average, 15% percent of trials that started reached the finish line to date. In the past 5 years, 12 clinical trials started and 3 clinical trials were completed. i.e. 25% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Surat Institute of Digestive Sciences" #1 sponsor was "Janssen Research & Development, LLC" with 5 trials, followed by "Galapagos NV" with 4 trials sponsored, "Pfizer" with 4 trials sponsored, "Arena Pharmaceuticals" with 2 trials sponsored and "Gilead Sciences" with 2 trials sponsored. Other sponsors include -2 different institutions and companies that sponsored additional 8 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Surat Institute of Digestive Sciences" #1 collaborator was "Gilead Sciences" with 4 trials as a collaborator, "Arena is a wholly owned subsidiary of Pfizer" with 2 trials as a collaborator, "Galapagos NV" with 1 trials as a collaborator and "Iqvia Pty Ltd" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 4 trials.

According to Clinical.Site data, the most researched conditions in "Surat Institute of Digestive Sciences" are "Ulcerative Colitis" (6 trials), "Crohn's Disease" (5 trials), "Colitis, Ulcerative" (2 trials), "Caloric Deficit" (1 trials) and "Chronic Hepatitis B" (1 trials). Many other conditions were trialed in "Surat Institute of Digestive Sciences" in a lesser frequency.

Most popular intervention types in "Surat Institute of Digestive Sciences" are "Drug" (19 trials), "Biological" (2 trials) and "Other" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (12 trials), "Filgotinib" (5 trials), "Etrasimod" (4 trials), "Guselkumab" (3 trials) and "Golimumab" (2 trials). Other intervention names were less common.

The vast majority of trials in "Surat Institute of Digestive Sciences" are 18 trials for "All" genders and 2 trials for "Male" genders.

Currently, there are NaN active trials in "Surat Institute of Digestive Sciences". undefined are not yet recruiting, 8 are recruiting, 5 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 6 completed trials in Surat Institute of Digestive Sciences, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Surat Institute of Digestive Sciences, 1 "Phase 1" clinical trials were conducted, 8 "Phase 2" clinical trials and 10 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 0 trials that are defined as “Not Applicable".